Transcutaneous immunization with bacterial ADP-ribosylating exotoxins, subunits, and unrelated adjuvants

Infection and Immunity

Volumn 68, Issue 9, 2000, Pages 5306-5313

  Scharton Kersten, T ^a   Yu, J M ^a   Vassell, R ^a   O'Hagan, D ^a   Alving, C R ^a   Glenn, G M ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; CHOLERA TOXIN; ENTEROTOXIN; EXOTOXIN; IMMUNOGLOBULIN G; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; LIPOPOLYSACCHARIDE; OLIGONUCLEOTIDE; TUMOR NECROSIS FACTOR ALPHA; VACCINE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ARTICLE; DNA SEQUENCE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENETICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; VACCINATION;

ADENOSINE DIPHOSPHATE RIBOSE; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; BACTERIAL TOXINS; BACTERIAL VACCINES; CHOLERA TOXIN; CYTOKINES; DIPHTHERIA TOXOID; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; IMMUNIZATION; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TETANUS TOXOID;

EID: 0033864920     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.9.5306-5313.2000     Document Type: Article

References (34)

1. Cutaneous vaccination: The skin as an Immunologically active tissue and the challenge of antigen delivery
2. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge
3. Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis
4. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp
5. CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity
6. The effect of cholera stool and culture filtrates on the skin of guinea pigs and rabbits
7. Interaction of Vibrio cholerae enterotoxin with cell membranes
8. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
9. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
10. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants
11. Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli
12. Bacterial toxins as mucosal adjuvants
13. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
14. Murine IgG subclass antibodies to antigens incorporated in liposomes containing lipid A
15. Skin immunization made possible by cholera toxin
16. Transcutaneous immunization with cholera toxin protects mice against lethal mucosal toxin challenge
17. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants
18. Advances in vaccine deliver: Transcutaneous immunization
19. Transcutaneous immunization
20. Transcutaneous immunization of animals: Opportunities and challenges
21. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines
22. Epidermal Langerhans cells: From neurons to nature's adjuvants
23. The role of CpG dinucleotides in DNA vaccines
24. New knowledge on pathogenesis of bacterial infections as applied to vaccine development
25. Vaccine developments
26. The mechanism of cholera toxin adjuvanticity
27. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults
28. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo
29. Principles of transcutaneous immunization using cholera toxin as an adjuvant
30. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection
31. Advances in vaccine adjuvants
32. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins
33. Immunostimulatory oligode-oxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms
34. Reducing the risk of unsafe injections in immunization programmes: The role of injection equipment